www.hep-druginteractions.org

Glecaprevir PK Fact Sheet

LIVERPOC


Page 1 of 2

Prepared July 2022

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Details

Generic Name	Glecaprevir
Trade Name	Maviret [®] , Mavyret [®] , (co-formulated with pibrentasvir)
Class	HCV NS3/4A inhibitor
Molecular Weight	838.87
Structure	FF



• X H₂O

Summary of Key Pharmacokinetic Parameters

Glecaprevir is available in a fixed-dose combination product with pibrentasvir.

Linearity/non-linearity	Glecaprevir AUC increases in a greater than dose-proportional manner (1200 mg once daily had 516-fold higher exposure than 200 mg once daily) which may be related to saturation of uptake and efflux transporters
Steady state	Achieved after 7 days of once daily dosing ¹
Plasma half-life	6-9 h
Стах	597 (114) ng/mL (geometric mean, %CV), in non-cirrhotic HCV-infected subjects
C24	3.07 (54), 5.50 (46), 3.72 (71) ng/mL (geometric mean, %CV), in healthy White, Han Chinese and Japanese adults, respectively 2
AUC	4800 (122) ng·h/mL (geometric mean, %CV), in non-cirrhotic HCV-infected subjects
Bioavailability	Not reported
Absorption	Compared to fasting, a moderate to high-fat meal increased glecaprevir exposure by 83-163%.
Protein Binding	97.5%
Volume of Distribution	Not reported
CSF:Plasma ratio	Not reported
Semen:Plasma ratio	Not reported
Renal Clearance	0.7% of dose excreted in urine
Renal Impairment	No dosage adjustment is required in patients with mild, moderate or severe renal impairment, including those on dialysis.
Hepatic Impairment	No dose adjustment is required in patients with mild hepatic impairment (Child-Pugh A). Glecaprevir is not recommended in patients with moderate hepatic impairment (Child-Pugh B) and is contraindicated in patients with severe hepatic impairment (Child-Pugh C).

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hep-druginteractions.org

Glecaprevir PK Fact Sheet

Prepared July 2022

Page 2 of 2 For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Metabolism and Distribution

Metabolised by	CYP3A (minimal) – glecaprevir is mainly eliminated by biliary/faecal excretion
Inducer of	None expected
Inhibitor of	Inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, BSEP. Weak inhibitor of CYP3A, CYP1A2, UGT1A1 (significant interactions are not expected with substrates of these enzymes). Significant inhibition of CYP2C9, CYP2C19, CYP2D6, UGT1A6, UGT1A9, UGT1A4, UGT2B7, OCT1, OCT2, OAT1, OAT3, MATE1 or MATE2K are not expected.
Transported by	P-gp, BCRP, OATP1B1, OATP1B3

References

Unless otherwise stated (see below), information is from: Maviret Summary of Product Characteristics, AbbVie Ltd. Mavyret Prescribing Information, AbbVie Inc.

- 1. Pharmacokinetic interactions and safety of coadministration of glecaprevir and pibrentasvir in healthy volunteers. Lin C, Dutta S, Zhao W et al. Eur J Drug Metab Pharmacokinet, 2018, 43(1): 81-90.
- 2. Pharmacokinetics, safety, and tolerability of glecaprevir and pibrentasvir in healthy White, Chinese, and Japanese adult subjects. Lin C, Dutta S, Ding B, et al. J Clin Pharmacol, 2017, 57(12): 1616-1624.